Khyzer B Aziz1, Orlyn C Lavilla2, James L Wynn3,4, Allison C Lure2, Daniel Gipson2, Diomel de la Cruz5. 1. Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA. 2. Department of Pediatrics, University of Florida, Gainesville, FL, USA. 3. Department of Pediatrics, University of Florida, Gainesville, FL, USA. James.wynn@peds.ufl.edu. 4. Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, USA. James.wynn@peds.ufl.edu. 5. Department of Pediatrics, University of Florida, Gainesville, FL, USA. ddelacruz@peds.ufl.edu.
Abstract
OBJECTIVE: To determine the relationship between maximum vasoactive-inotropic (VISmax) and mortality in extremely premature (<29 weeks completed gestation), extremely low birth weight (ELBW, <1000 g) infants. STUDY DESIGN: Single center, retrospective, and observational cohort study. RESULTS: We identified 436 ELBW, <29 week, inborn infants cared for during the study period. Compared to infants with VISmax of 0, the frequency of mortality based on VISmax ranged from 3.3-fold to 46.1-fold. VISmax > 30 was associated with universal mortality. Multivariable modeling that included gestational age, birth weight, and VISmax revealed significant utility to predict mortality with negative predictive value of 87.0% and positive predictive value of 84.8% [adjusted AUROC: 0.90, (0.86-0.94)] among patients that received vasoactive-inotropic treatment. CONCLUSION: VISmax is an objective measure of hemodynamic/cardiovascular support that was directly associated with mortality in extremely premature ELBW infants. The VISmax represents an important step towards neonatal precision medicine and risk stratification of extremely premature ELBW infants.
OBJECTIVE: To determine the relationship between maximum vasoactive-inotropic (VISmax) and mortality in extremely premature (<29 weeks completed gestation), extremely low birth weight (ELBW, <1000 g) infants. STUDY DESIGN: Single center, retrospective, and observational cohort study. RESULTS: We identified 436 ELBW, <29 week, inborninfants cared for during the study period. Compared to infants with VISmax of 0, the frequency of mortality based on VISmax ranged from 3.3-fold to 46.1-fold. VISmax > 30 was associated with universal mortality. Multivariable modeling that included gestational age, birth weight, and VISmax revealed significant utility to predict mortality with negative predictive value of 87.0% and positive predictive value of 84.8% [adjusted AUROC: 0.90, (0.86-0.94)] among patients that received vasoactive-inotropic treatment. CONCLUSION: VISmax is an objective measure of hemodynamic/cardiovascular support that was directly associated with mortality in extremely premature ELBW infants. The VISmax represents an important step towards neonatal precision medicine and risk stratification of extremely premature ELBW infants.
Authors: Ryan J Butts; Mark A Scheurer; Andrew M Atz; Sinai C Zyblewski; Thomas C Hulsey; Scott M Bradley; Eric M Graham Journal: Pediatr Cardiol Date: 2012-02-15 Impact factor: 1.655
Authors: Ravi M Patel; Sarah Kandefer; Michele C Walsh; Edward F Bell; Waldemar A Carlo; Abbot R Laptook; Pablo J Sánchez; Seetha Shankaran; Krisa P Van Meurs; M Bethany Ball; Ellen C Hale; Nancy S Newman; Abhik Das; Rosemary D Higgins; Barbara J Stoll Journal: N Engl J Med Date: 2015-01-22 Impact factor: 91.245
Authors: Michael G Gaies; Howard E Jeffries; Robert A Niebler; Sara K Pasquali; Janet E Donohue; Sunkyung Yu; Christine Gall; Tom B Rice; Ravi R Thiagarajan Journal: Pediatr Crit Care Med Date: 2014-07 Impact factor: 3.624
Authors: G Wernovsky; D Wypij; R A Jonas; J E Mayer; F L Hanley; P R Hickey; A Z Walsh; A C Chang; A R Castañeda; J W Newburger; D L Wessel Journal: Circulation Date: 1995-10-15 Impact factor: 29.690
Authors: Michael G Gaies; James G Gurney; Alberta H Yen; Michelle L Napoli; Robert J Gajarski; Richard G Ohye; John R Charpie; Jennifer C Hirsch Journal: Pediatr Crit Care Med Date: 2010-03 Impact factor: 3.624
Authors: Barbara J Stoll; Nellie I Hansen; Edward F Bell; Michele C Walsh; Waldemar A Carlo; Seetha Shankaran; Abbot R Laptook; Pablo J Sánchez; Krisa P Van Meurs; Myra Wyckoff; Abhik Das; Ellen C Hale; M Bethany Ball; Nancy S Newman; Kurt Schibler; Brenda B Poindexter; Kathleen A Kennedy; C Michael Cotten; Kristi L Watterberg; Carl T D'Angio; Sara B DeMauro; William E Truog; Uday Devaskar; Rosemary D Higgins Journal: JAMA Date: 2015-09-08 Impact factor: 56.272
Authors: Amanda M McIntosh; Suhong Tong; Sara J Deakyne; Jesse A Davidson; Halden F Scott Journal: Pediatr Crit Care Med Date: 2017-08 Impact factor: 3.624
Authors: Orlyn C Lavilla; Khyzer B Aziz; Allison C Lure; Daniel Gipson; Diomel de la Cruz; James L Wynn Journal: Am J Respir Crit Care Med Date: 2022-01-01 Impact factor: 21.405